About Allist
Profile
Awards & Recognition
History
Science Advisory Broad
R & D
Clinical Trial
Clinical Study
Manufacturing
Collaborations & Partnership
Products
Furmonertinib
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
English
中文
菜单
Search
Home
About Allist
Profile
Awards & Recognition
History
Science Advisory Broad
R & D
Clinical Trial
Clinical Study
Manufacturing
Collaborations & Partnership
Products
Furmonertinib
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
English
Advancing Long Life with
Innovation of Science and Technology
An innovative
biopharmaceutical company
News
Spotlight for Furmonertinib – NSCLC with EGFR Exon 20 Insertions Data Public at 2023 WCLC
2023/09/10
Furmonertinib Received New Indication IND Approval by CDE – Comprehensive Cover, Global Synchronization
2023/04/04
Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)
2023/03/02
Allist Pharmaceuticals Annouced Today the Signing of a License Agreement with Abbisko Therapeutics for a New Generation of EGFR TKI, called ABK3376
2023/03/01
Furmonertinib Published in Prestigious International Journal Once Again
2022/08/05
Ivesa® won the "14th China Health Forum - Top 10 New Drugs (in China)”
2022/08/04
Allist listed on “TOP 100 Hardcore Technology Enterprises in Shanghai in 2022"
2022/07/22
